MDACC Study No:2012-0822 ( NCT No: NCT01751308)
Title:A Phase I -2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric
Patients with Refractory Solid Tumors including Tumors of the Central Nervous
Principal Investigator:Cynthia E. Herzog
Treatment Agent:Cabazitaxel
Study Status:Closed
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of cabazitaxel that can be given to children with refractory or recurrent solid
tumors. Researchers also want to learn about the safety of the drug and the
amount of study drug in the body at different time points.

This is the first study using cabazitaxel in children.

Cabazitaxel is designed to interfere with the growth of cancer cells by
stopping cell division.
Hide details for General InformationGeneral Information

Disease Group:Pediatrics
Phase of Study:Phase I/Phase II
Treatment Agents:Cabazitaxel
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Children's Hospital Colorado
Sanofi US Services Inc
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Cynthia E. Herzog
For Clinical Trial Enrollment:713-792-6620
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults